Analysts impressed by Biogen after full data on Alzheimer’s drug Lecanemab By Investing.com
© Reuters Analysts impressed by Biogen (BIIB) after full data on Alzheimer’s drug Lecanemab By Senad Karaahmetovic Biogen (NASDAQ:) yesterday presented detailed results from the Ph3 Clarity AD confirmatory trial. According to the company, Lecanemab “reduced […]
